Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
about
Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer.ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo.Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells.
P2860
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase I trial of volasertib, a ...... pharmacokinetics and activity
@ast
Phase I trial of volasertib, a ...... pharmacokinetics and activity
@en
type
label
Phase I trial of volasertib, a ...... pharmacokinetics and activity
@ast
Phase I trial of volasertib, a ...... pharmacokinetics and activity
@en
prefLabel
Phase I trial of volasertib, a ...... pharmacokinetics and activity
@ast
Phase I trial of volasertib, a ...... pharmacokinetics and activity
@en
P2093
P2860
P1476
Phase I trial of volasertib, a ...... pharmacokinetics and activity
@en
P2093
Ahmad Awada
Gerd Munzert
Herlinde Dumez
Jessica Cescutti
Jo Costermans
Kathleen Forceville
Korinna Pilz
Marie-Anne Meeus
Philippe G Aftimos
P2860
P2888
P304
P356
10.1007/S10637-015-0223-9
P577
2015-03-22T00:00:00Z
P5875
P6179
1049442217